HQL vs SFST
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HQL presents as a deep-value opportunity, anchored by a stable Piotroski F-Score of 6/9 and a significant valuation gap, with a current price of $17.56 trading well below its Graham Number ($33.01) and Intrinsic Value ($82.31). While the company exhibits severe operational anomalies—specifically a -69.90% revenue collapse and a deeply negative operating margin—the massive earnings growth and low P/E ratio (6.29) suggest the entity is benefiting from significant investment gains rather than core fee income. The high dividend yield of 12.76% is supported by a sustainable payout ratio, though the bearish technical trend (10/100) suggests a period of consolidation or price correction is underway.
SFST presents a conflicting profile characterized by a weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial health. Despite this, the stock appears undervalued, trading at $56.68, which is below both its Graham Number ($65.59) and its growth-based Intrinsic Value ($125.67). While YoY earnings growth is exceptionally strong at 83.10%, this is offset by bearish insider selling and a very weak technical trend (10/100). The company is currently a high-growth value play with concerning underlying health metrics.
Compare Another Pair
Related Comparisons
HQL vs SFST: Head-to-Head Comparison
This page compares Abrdn Life Sciences Investors (HQL) and Southern First Bancshares, Inc. (SFST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.